BEDFORD, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Oxford Biomedica Solutions LLC, offers The Full Solution™ suite of services, which includes end-to-end development and manufacturing capabilities for cell and gene therapy. The scientific team uses an innovative approach to develop and produce Adeno-Associated Virus (AAV) vectors used in the treatment of patients. As part of our focus on innovation, a novel, dual-plasmid system has been developed for use in the transfection step of the manufacturing process. This has resulted in significantly increased AAV vector productivity and percentage of full capsids packaged over traditional triple-plasmid transfection. The peer-reviewed journal article was accepted on May 8th in Molecular Therapy – Methods and Clinical Development. “We are excited to have the first of several peer-reviewed journal articles published, which showcases our innovations, and in turn, allows us to achieve a bioreactor titer of >1E15 vg/L and total vg of 1.5E17 in drug substance (DS) per 500L batch,” said Tim Kelly, CEO of Oxford Biomedica Solutions.
Contact:
Oxford Biomedica Solutions
www.oxbsolutions.com
T: +781.428.4536/ E: solutions.partnering@oxb.com
About Oxford Biomedica Solutions
Oxford Biomedica Solutions offers a plug and play platform that is capable of achieving both high titer and high product quality vector for partners. The platform has already been proven with six INDs and CTAs. High titer, high product quality, proven expertise, and speed are the foundation of the platform. This unique platform and fully integrated end-to-end capabilities, from vector design and process development through to clinical trials, are now available to partners. For more information, contact us at solutions.partnering@oxb.com or visit our website at oxbsolutions.com.
